Phase 2 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with systemic lupus erythematosus (lupus) for at least 6 months.
- People who have been on a stable lupus treatment for at least 28 days before the first dose of the trial treatment.
- People whose lupus disease activity falls within a specific range, measured by a scoring system called SLEDAI-2000, with a score between 4 and 12 (confirm with trial site).
- People who are generally in good health apart from their lupus diagnosis.
Who may not be able to join:
- People with a severe form of lupus.
- People who have another significant autoimmune disease in addition to lupus.
- People who have a serious, uncontrolled, or unstable condition affecting any organ or body system.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sheng Chen, Ph.D, Renji Hospital Shanghai Jiaotong University School of Medical
Phone: 240-505-6608
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.